Previous 10 | Next 10 |
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick “Fred” T. Fiedorek, M.D....
2023-09-11 11:13:02 ET Summary Verve Therapeutics focuses on gene editing therapies for cardiovascular disease, backed by solid liquidity and Phase 1b trials. Financials are strong but face risk from high R&D expenses, long-term trial costs, and market competition with establi...
2023-08-31 10:30:00 ET Cathie Wood is one of the most influential investors in the area of high tech, and her Ark Innovation ETF has been a top performer this year. One of the stocks that Wood has been buying aggressively recently is Verve Therapeutics (NASDAQ: VERV) , a company...
2023-08-10 10:50:47 ET Verve Therapeutics press release ( NASDAQ: VERV ): Q2 GAAP EPS of -$0.87 beats by $0.05 . Revenue of $2.09M beats by $1.42M . For further details see: Verve Therapeutics GAAP EPS of -$0.87 beats by $0.05, revenue of $2.09M beats by ...
heart-1 Initial Clinical Data Expected in the Fourth Quarter of 2023 Preclinical Studies and Clinical Operations Activities Underway to Support Initiation of Clinical Trials for VERVE-102 and VERVE-201 in 2024 Lp(a) Program Advancing in Collaboration with Lilly; Received $60 Mil...
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer,...
2023-07-15 04:25:01 ET Summary The memo reads that the bear market has been cancelled, and there are few who are as happy about the change in fortunes as Cathie Wood and ARK Funds. Her flagship ARKK fund, as well as other ARK family funds, have had an impressive run lately and wer...
2023-07-13 09:53:00 ET From June 21 to July 7, growth-stock portfolio manager Cathie Wood bought shares of Verve Therapeutics (NASDAQ: VERV) a total of seven times, building up the position held in her ARK Innovation ETF . The biotech now accounts for just over 0.5% of her portf...
2023-07-04 04:57:46 ET Summary Verve Therapeutics announced a partnership with Eli Lilly & Co., focusing on in-vivo gene editing technology, but investors remain concerned about the FDA's clinical hold on Verve's PCSK9 candidate VERVE-101. The partnership could provide Verve w...
2023-06-26 05:24:52 ET Summary I had a short-term thesis on VERV stock, and took a small position in February. I am not so sure it makes sense to hold on to VERV any longer. I will not be making a loss, but will exit at almost buy price. My Verve Therapeutics ( VERV ...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...